Mabion SA (272) AI Stock Analysis

Mabion SA

(Frankfurt:272)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Operational EfficiencyMaintaining a positive EBITDA margin indicates operational efficiency, allowing the company to cover its operating expenses and potentially improve profitability over time.

Negative Factors

Declining Gross Profit MarginA declining gross profit margin indicates rising costs or pricing pressures, which could erode profitability and limit resources available for growth initiatives.

Mabion SA (272) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 28.89M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.3
Beta (1Y): 0.17
Revenue Growth: 57.49%
EPS Growth: 12.27%
Country: Germany
Employees: 202
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Mabion SA Business Overview & Revenue Model

Company Description

Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing...

Mabion SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:272 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PL:RVU	37Underperform	PLN 392.58M	-5.39	-139.66%	―	-11.57%	43.60%
PL:CTX	34Underperform	PLN 337.20M	-6.57	-132.32%	―	-81.93%	-3.31%

* Healthcare Sector Average

Performance Comparison

DE:272 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:272	Mabion SA	1.73	-0.16	-8.44%
PL:RVU	Ryvu Therapeutics SA	16.22	-8.58	-34.60%
PL:SCP	Scope Fluidics SA	140.20	-12.40	-8.13%
PL:SVE	Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.	2.63	-1.39	-34.70%
PL:CTX	Captor Therapeutics SA	51.00	2.10	4.29%
PL:MOC	OncoArendi Therapeutics SA	5.68	-0.55	-8.83%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Mabion SA AI Stock Analysis